Both type I and type II tumors develop from extraovarian tissue that implants on the ovary. Both for LGSC and HGSC, the fallopian tube appears to be

Size: px
Start display at page:

Download "Both type I and type II tumors develop from extraovarian tissue that implants on the ovary. Both for LGSC and HGSC, the fallopian tube appears to be"

Transcription

1

2 Recent studies have led to the development of a new paradigm for the pathogenesis and origin of EOC, based on a dualistic model of carcinogenesis that divides EOC into 2 broad categories designated types I and II. Type I tumors (low grade serous, low grade endometrioid, clear cell and mucinous carcinomas, and Brenner tumors) are generally indolent (but chemoresistant!)and present in stage I (tumor confined to the ovary). They are characterized by specific mutations but rarely TP53 and are relatively stable genetically.

3 Both type I and type II tumors develop from extraovarian tissue that implants on the ovary. Both for LGSC and HGSC, the fallopian tube appears to be the source of the tumors

4 The mounting evidence that ovarian cancer does not develop in the ovary and the lack of success of ovarian cancer screening provide a strong argument for directing efforts at prevention Chan A, et al. Obstet Gynecol 2012

5 Reduction in the future risk of ovarian cancer is the single most common reason for normal ovaries to be removed at the time of hysterectomy, particularly in the post-menopausal women Parker WH, et al. Curr Opin Obstet Gynecol 2007 In women not at increased risk of ovarian cancer the disadvantages of prophylactic oophorectomy outweigh the advantages up to the age of 65 years. Parker WH, et al. Curr Opin Obstet Gynecol 2007 Over all, women with oophorectomy before 55 had about 8.5% excess mortality compared with ovarian conservation. Women with oophorectomy before 59 had 4% excess mortality. Harman H., et al. Climateric 2005

6 Nevertheless, the effects of salpingectomy on ovarian functions are still controversial. To the best of our knowledge, there are no strong evidences on the effect of salpingectomy on surgical outcomes of a standard hysterectomy

7 It has been hypothesized that the destruction of the fallopian tube reduces the uteroovarian arterial blood flow in the mesosalpinx, thereby leading to tissue damage to the ovary. In addition, venous drainage may be compromised because venous plexuses are located near the arteries. Cattanach JF, Milne BJ. Contraception 1988 However, given the dual ovarian blood supply, guaranteed both by infundibolopelvic vessels and from the ovarian branch of the uterine artery, and considering the additional anastomosis of these vessels at the tubal level, at the time of hysterectomy with salpingectomy, the whole infundibolopelvic blood volume, normally distributed between tubes and ovaries, becomes available to the ovaries. Dietl J. Fertil Steril 2014

8 In order to validate a new preventive strategy, it is necessary to objectively asses in risk-reducing salpingectomy to ensure that these changes in surgical practice are both costeffective and safe to women Assess the frequency of, and model the risk associated with STICs in both women at high risk and baseline risk for ovarian cancer and monitor gradual changes in the distribution of tumor histologies and patient history at diagnosis as a result of this initiative, and eventually determine if we have decreased the number of ovarian cancers diagnosed per year.

9 We retrospectively compared data of 79 patients who underwent TLH plus bilateral salpingectomy (group A),with those of 79 women treated by standard TLH without adnexectomy (stlh) (group B). The goal of the study was to evaluate if ovarian function and surgical outcomes are modified by the addiction of bilateral salpingectomy to the standard technique.

10 The data for these patients were compared with those of 79 women treated by standard TLH without adnexectomy, matched for uterine weight

11 Morelli M. et al. Gynecol Oncol 2013

12 A prior analysis conducted on our data demonstrated a post-operative AMH levels average decrease of 9% in women submitted to total laparoscopic hysterectomy with adnexal preservation (standard procedure). Assuming a 10% decrease with this procedure, and a maximal clinically acceptable decreasing for equivalence of 15% in AMH levels in women after salpingectomy, a sample of at least 69 patients per group would have given 95% power and a one-sided significance level of 10%. In our study, given a sample size of 79 patients in each group, power model resulted of 96.8%.

13 Nineteen patients (24%) submitted to TLH plus salpingectomy in 2010, 22 (28%) in 2011 and 38 (48) in 2012 Seventy-nine (100%) patients re-called to be submitted again to ovarian reserve evaluation in 2015 Seventy-one (89.9%) women accepted to participate and were evaluated Eight (10.1%) women refused to participate to the follow-up study Both women with and without menopausal symptoms have been analyzed. In ovulating women, ovarian reserve has been evaluated when early follicular phase has been confirmed by the presence of serum E 2 level <60 pg/ml and P<1 ng/ml, in conjunction with ultrasound confirmation of the absence of a dominant follicle >10mm in any of the ovaries. Venturella R. et al. Unpublished data!

14

15 The innovation introduced by our algorithm is that the final output is not a generic definition of good or poor ovarian reserve, like others tests already do. Our test answers with a number, the patient s OvAge.

16 Parameters Mean values±sd Age at surgery (years) ± 2.40 Age at follow-up (years) ± 2.15 OvAge at follow-up (years) ± 2.12 FSH at follow-up (mu/ml) ± AMH at follow-up (ng/ml) 0.12 ± D AFC at follow-up (n.) 1.91 ± 1.28 VI at follow-up (%) 2.80 ± 5.32 FI at follow-up (1-100) ± 5.88 VFI at follow-up (1-100) 0.56 ± 1.12 Venturella R. et al. Unpublished data!

17 According to this observation, simple salpingectomy might not offer maximal protection! Recent evidence suggests that not only the fimbrial end of the tube but also the soft tissues adjacent to the ovary in the mesosalpinx can give rise to neoplasms

18 Objective: To study the effects of the radical excision of soft tissues adjacent to the ovary and fallopian tube on ovarian function and surgical outcomes in women undergoing laparoscopic bilateral prophylactic salpingectomy. Design: Randomized-controlled trial (NCT ) Setting: Magna Graecia University of Catanzaro Patients: One-hundred-eighty-six women undergoing laparoscopic surgery for uterine myoma (n=143) or tubal surgical sterilization (n=43) between March 2014 and January Main Outcome Measures: Ovarian reserve modification (Δ) prior to and post surgery was assessed as primary outcome. The operative time, variation of the haemoglobin level (ΔHb), postoperative hospital stay, postoperative return to normal activity, and complication rate were assessed as secondary outcomes. Venturella R. et al. Under review on Fertil Steril 2015

19 Patients were randomly divided into two groups. In Group A (n=91), standard salpingectomy was performed. In Group B (n=95), the mesosalpinx was removed within the tubes. Prior to and 3 months post surgery, AMH, FSH, 3D AFC, Vascular Index (VI), Flow Index (FI), Vascular-Flow Index (VFI) and OvAge were recorded for each patient. Venturella R. et al. Under review on Fertil Steril 2015

20 Baseline data Parameters Standard Salpingectomy Radical Salpingectomy p Group A (n.91) Group B (n.95) Age (years) ± ± Parity (children) 2.73 ± ± AMH (ng/ml) 0.93 ± ± FSH (miu/ml) ± ± E 2 (pg/ml) 23.8± ± AFC (n) 7.80 ± ± VI (%) 0.97 ± ± FI (0-100) ± ± VFI (0-100) 0.58 ± ± OvAge (years) ± ± All data are expressed as mean and SD Venturella R. et al. Under review on Fertil Steril 2015

21 Primary and secondary outcomes measures Parameters Standard Salpingectomy Radical Salpingectomy p Group A (n.91) Group B (n.95) Δ AMH (ng/ml) 0.09 ± ± Δ FSH (miu/ml) 0.47 ± ± Δ AFC (n) 0.33 ± ± Δ VI (%) 0.10 ± ± Δ FI (0-100) 0.74 ± ± Δ VFI (0-100) 0.08 ± ± Δ OvAge (years) 0.03 ± ± Operative time (min) ± ± Δ Hb (g/dl) 1.52± ± Postoperative hospital stay (days) 2.07± ± Postoperative return to normal activity (days) 9.20± ± Complication rate (%) All data are expressed as mean and SD Venturella R. et al. Under review on Fertil Steril 2015

22 Even when the surgical excision includes the removal of the mesosalpinx, salpingectomy does not damage the ovarian reserve. Moreover, radical salpingectomy with excision of the mesosalpinx did not alter blood loss, hospitalization stay, or return to normal activities. A demonstration of the absence of any detrimental effects of the radicalization of the currently practiced standard technique for salpingectomy represents a new and important step in the long but exciting process that may lead to one of the most important scientific revolutions in gynaecological surgery of the last few centuries. Venturella R. et al. Under review on Fertil Steril 2015

23 The finding of equivalent outcomes in patients undergoing hysterectomy and salpingectomy, compared to hysterectomy alone, which was documented in the study by Morelli et al, is of general interest to the gynecology community, at this particular time, because of recent changes in our understanding of the histogenesis of HGSC. With regard to whether there are implications for subsequent ovarian function or an increased likelihood of complications, Morelli et al. have demonstrated that there are no detectable complications of performing salpingectomy at the same time as hysterectomy, the data of which can be used immediately in counseling patients.

24 Parker W. Menopause 2014

25 The objective of the study was to examine obstetrician-gynaecologists knowledge, opinions, and practice patterns relating to opportunistic salpingectomy in the general population. An anonymous electronic survey was sent to all Obstetrics and Gynaecology Residency Program Directors, Full and Associate Professors, Delegates of FIGO, SIGO and AOGOI. The survey was available online for completion between January 3 and July 2, 2014 More than two thousand colleagues invited to participate A total of 479 surveys were returned The largest survey published on the topic!!! Venturella R. et al. Eur J Canc Prev 2015 In Press

26 PRACTICE SETTING TYPOLOGY Associate professors 12% Full professors 6% Residents 3% Do you usually perform PBS in association with a hysterectomy without oophorectomy for benign indications? No 18% Academic obstetricians and gynecologists 34% Hospital obstetricians and gynecologists 45% Yes 82% Venturella R. et al. Eur J Canc Prev 2015 In Press

27 IF YES, WHY DO YOU PERFORM PBS? IF NO, WHY NOT? To reduce the risk of hydrosalpinges ; 66 To reduce the risk of pelvic pain ; 38 There is no benefit; 47 It increases the risk of surgical complications ; 19 It increases operative time; 14 To reduce the risk of reoperation ; 29 To reduce the risk of cancer ; 371 Venturella R. et al. Eur J Canc Prev 2015 In Press The risk of reoperation is the same regardless of whether bilateral salpingectomy is performed ; 24 It does not decrease the risk of ovarian and peritoneal cancers; 9

28 Do you believe there are additional risks to performing PBS in addition to hysterectomy or other form of tubal sterilization? Yes; 47 It had happened before this survey to have information on the new and the possibility of introducing PBS as a preventive measure? Yes, I have heard about it at a conference ; 35 Yes, I was asked about by one or more patients ; 7 No, I had never heard of PBS; 21 No; 430 Venturella R. et al. Eur J Canc Prev 2015 In Press I have read the literature but I was not aware of the safety data published about; 97 Yes, I was aware of the safety data published about; 303

29 Salpingectomy as a primary method of sterilization has not been considered routinely until the past few years. Interestingly, for individuals in whom sterilization fails, it has been long been considered that bilateral salpingectomy is the preferred method to ensure definitive treatment. A recent case-control study over a 45-year period found that the risk of serous ovarian cancer after salpingectomy was reduced by more than 60% as compared with a group of women who were either not sterilized or had a tubal interruption sterilization. Lessard-Anderson et al,. Gynecol Oncol 2013

30

31 The ideal BRCA carrier candidate for RRS would be: a premenopausal woman with a prior risk-reducing mastectomy desiring ovarian preservation for the medical and cognitive benefits The ideal trial to verify equivalence of salpingectomy (RRS) and salpingooophorectomy (PBSO) should include: Salpingectomy once reproductive desire is accomplished (<40 ys) CA125 and ETV every 6 months Ovariectomy at 40 years with inspection for pathologic evidence of disease If no evidence of ovarian cancer is found in the original cohort of RRS women equivalency trial of RSS to RRSO without the second surgery. Anderson CK et al. Int J Gyn Cancer 2013

32 Anderson CK et al. Int J Gyn Cancer 2013

33 RRSO between the ages of 35 and 40 years is recommended for risk reduction in women at increased genetic risk of ovarian cancer. The age of RRSO may also be individualized according to the earliest age of onset in the family and personal choices. Salpingectomy can be considered at the completion of childbearing in women at increased genetic risk of ovarian cancer who do not agree to salpingooophorectomy. However, this is not a substitute for oophorectomy, which should still be performed as soon as the woman is willing to accept menopause, preferably by the age of 40 years. Women delaying or refusing risk-reducing oophorectomy will not receive the breast cancer risk reduction provided by oophorectomy.

34 We are enrolling the first 80 patients who agree to implement PBS to LPS cholecystectomy (study group), starting from January 1, Other 80 patients who will ask us to undergo cholecystectomy without the addiction of PBS will constitute the control group

35 We are working with regional and national competent offices to develop a unique code for salpingectomy performed for OC risk reduction. To address specific genomic and transcriptomic risk pattern, different by BRCA mutation, in patients with HGSC To validate already promising serum biomarkers and to try to address a reliable cytological method to screen p53 positivity on tubal cells (both obtained by cervicovaginal thin prep and by hysteroscopic collection)

36

37

Inherited Ovarian Cancer Diagnosis and Prevention

Inherited Ovarian Cancer Diagnosis and Prevention Inherited Ovarian Cancer Diagnosis and Prevention Dr. Jacob Korach - Deputy director Gynecologic Oncology (past chair - Israeli Society of Gynecologic Oncology) Prof. Eitan Friedman - Head, Oncogenetics

More information

Current Concept in Ovarian Carcinoma: Pathology Perspectives

Current Concept in Ovarian Carcinoma: Pathology Perspectives Current Concept in Ovarian Carcinoma: Pathology Perspectives Rouba Ali-Fehmi, MD Professor of Pathology The Karmanos Cancer Institute, Wayne State University School of Medicine Current Concept in Ovarian

More information

Christine Herde, MD, FACOG

Christine Herde, MD, FACOG Christine Herde, MD, FACOG Vice Chair, Department of OB/GYN CareMount Medical, Mount Kisco, NY Assistant Director of OB/GYN, Mount Sinai Health System at CareMount Medical 1. OSE presumption that Ovarian

More information

Disclosures/Conflict of Interest. Learning Objectives 10/2/2015. Opportunistic salpingectomy for ovarian cancer prevention Jessica N McAlpine, UBC

Disclosures/Conflict of Interest. Learning Objectives 10/2/2015. Opportunistic salpingectomy for ovarian cancer prevention Jessica N McAlpine, UBC Opportunistic salpingectomy for ovarian cancer prevention Jessica N McAlpine, UBC Disclosures/Conflict of Interest No conflicts of interest to declare No discussion re off label use and/or investigational

More information

Tumori eredofamiliari: sorveglianza di donne ad alto rischio

Tumori eredofamiliari: sorveglianza di donne ad alto rischio Tumori eredofamiliari: sorveglianza di donne ad alto rischio 14/01/2018 Dott Matteo Generali AUSL Modena Carpi U.O. Ostetricia e Ginecologia Screening for gynaecologic cancer in genetically predisposed

More information

Opportunistic Risk Reduction Salpingectomy and Ovarian Cancer

Opportunistic Risk Reduction Salpingectomy and Ovarian Cancer Opportunistic Risk Reduction Salpingectomy and Ovarian Cancer G. Kevin Donovan, MD, MA Kevin FitzGerald, SJ, Ph.D., Ph.D. Daniel Sulmasy, MD, Ph.D. Ovarian cancer has the highest mortality rate of all

More information

Ivyspring International Publisher. Introduction. Journal of Cancer 2018, Vol. 9. Abstract

Ivyspring International Publisher. Introduction. Journal of Cancer 2018, Vol. 9. Abstract 141 Ivyspring International Publisher Research Paper Journal of Cancer 2018; 9(1): 141-147. doi: 10.7150/jca.21187 Opportunistic salpingectomy at benign gynecological surgery for reducing ovarian cancer

More information

BRCA mutation carrier patient: How to manage?

BRCA mutation carrier patient: How to manage? BRCA mutation carrier patient: How to manage? Clinical Case Presentation Katarzyna Sosińska-Mielcarek Department of Oncology and Radiotherapy University Clinical Center Gdansk, Poland esmo.org DISCLOSURE

More information

Gynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health

Gynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Controversies in Women s Health Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive

More information

BSO, HRT, and ERT. No relevant financial disclosures

BSO, HRT, and ERT. No relevant financial disclosures BSO, HRT, and ERT Jubilee Brown, MD Professor & Associate Director, Gynecologic Oncology Levine Cancer Institute at the Carolinas HealthCare System Charlotte, North Carolina No relevant financial disclosures

More information

Gynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:

Gynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive

More information

Oophorectomy or salpingectomy which makes more sense?

Oophorectomy or salpingectomy which makes more sense? Oophorectomy or salpingectomy which makes more sense? During hysterectomy for benign indications, many surgeons routinely remove the ovaries to prevent cancer. Here s what we know about this practice.

More information

SCREENING FOR OVARIAN CANCER DR MACİT ARVAS

SCREENING FOR OVARIAN CANCER DR MACİT ARVAS SCREENING FOR OVARIAN CANCER DR MACİT ARVAS Ovarian cancer is the leading cause of death from gynecologic malignancy In 2008, ovarian cancer was the seventh common cancer in women worldwide There were

More information

Epithelial Ovarian Cancer 8/2/2013. Tu-be or Not Tu-be: Is the Fallopian Tube the Source of Ovarian Cancer?

Epithelial Ovarian Cancer 8/2/2013. Tu-be or Not Tu-be: Is the Fallopian Tube the Source of Ovarian Cancer? Tu-be or Not Tu-be: Is the Fallopian Tube the Source of Ovarian Cancer? Ann E. Smith Sehdev, MD Director, Center for Gynecologic Pathology Cascade Pathology, Portland, Oregon Ann E. Smith Sehdev has no

More information

Is It Time To Implement Ovarian Cancer Screening?

Is It Time To Implement Ovarian Cancer Screening? Is It Time To Implement Ovarian Cancer Screening? Prof Dr Samet Topuz Istanbul Medıcal Faculty Department Of Obstetrics and Gynecology ESGO Prevention in Gynaecological Malignancies September 08 2016 Antalya

More information

Biology Response Controversies and Advances

Biology Response Controversies and Advances Biology Response Controversies and Advances in BRCA related ovarian cancer Lessons learned and future directions Michael Friedlander The Prince of Wales Hospital and Royal Hospital for Women Sydney BREAST-CANCER

More information

FAQ-Protocol 3. BRCA mutation carrier guidelines Frequently asked questions

FAQ-Protocol 3. BRCA mutation carrier guidelines Frequently asked questions ULast updated: 09/02/2015 Protocol 3 BRCA mutation carrier guidelines Frequently asked questions UQ: How accurate are the remaining lifetime and 5 year breast cancer risks in the table? These figures are

More information

Ask the Experts Obstetrics & Gynecology

Ask the Experts Obstetrics & Gynecology 1 Management of the Adnexal Mass James H. Liu, MD, and Kristine M. Zanotti, MD June 2011 Volume 117 Issue 6 Pages 1413 28 Click Here to Read the Full Article Questions written by: Rini Banerjee Ratan,

More information

Disclosure. Objectives

Disclosure. Objectives Charles A. Leath, III, MD, MSPH Associate Professor University of Alabama at Birmingham Disclosure I have no potential financial or other conflicts of interest. The view(s) expressed herein are those of

More information

Surgery to Reduce the Risk of Ovarian Cancer. Information for Women at Increased Risk

Surgery to Reduce the Risk of Ovarian Cancer. Information for Women at Increased Risk Surgery to Reduce the Risk of Ovarian Cancer Information for Women at Increased Risk Centre for Genetics Education NSW Health 2017 The Centre for Genetics Education NSW Health Level 5 2C Herbert St St

More information

Long-Term Health Outcomes of Surgical Menopause

Long-Term Health Outcomes of Surgical Menopause Long-Term Health Outcomes of Surgical Menopause Vanessa Jacoby, MD, MAS Associate Professor Obstetrics, Gynecology, and Reproductive Sciences University of California, San Francisco None Disclosures Overview

More information

Key Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer

Key Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer Gynecologic management of women with inherited risk of gynecologic cancer C. Bethan Powell MD Kaiser Permanente Northern California Gynecologic Oncology Program Lead, Kaiser Permanente Northern California

More information

Surgery to reduce the risk of ovarian cancer

Surgery to reduce the risk of ovarian cancer Surgery to reduce the risk of ovarian cancer INFORMATION FOR PATIENTS This leaflet is designed to answer questions you may have about surgery to reduce your risk of ovarian cancer. You may be considering

More information

What is the gynecologist s role in the care of BRCA previvors?

What is the gynecologist s role in the care of BRCA previvors? What is the gynecologist s role in the care of BRCA previvors? Here, your patient s options for surgery and your best options for her follow-up care and ongoing surveillance OBG Manag. Sept 2013;25(9):10-14.

More information

Ovarian, Peritoneal, and Fallopian Tube Epithelial Cancer (OPT)

Ovarian, Peritoneal, and Fallopian Tube Epithelial Cancer (OPT) Ovarian, Peritoneal, and Fallopian Tube Epithelial Cancer (OPT) ACOG District II 2 Learning Objectives At the end of this clinical presentation, obstetrician gynecologists and other women s health care

More information

OVARIAN CANCER Updates in Screening, Early Detection and Prevention

OVARIAN CANCER Updates in Screening, Early Detection and Prevention UW MEDICINE SUSAN PATRICIA TECK MEMORIAL LECTURE October 2017 OVARIAN CANCER Updates in Screening, Early Detection and Prevention BARBARA GOFF, MD Seattle Gynecologic Society March 2018 OVARIAN CANCER

More information

The Diagnostic Challenges of Low Grade and High Grade Tubo-Ovarian Serous Carcinomas. W Glenn McCluggage Belfast, Northern Ireland

The Diagnostic Challenges of Low Grade and High Grade Tubo-Ovarian Serous Carcinomas. W Glenn McCluggage Belfast, Northern Ireland The Diagnostic Challenges of Low Grade and High Grade Tubo-Ovarian Serous Carcinomas W Glenn McCluggage Belfast, Northern Ireland Enterprise Interest None OVARIAN SEROUS CARCINOMA (OSC) RECENT DEVELOPMENTS

More information

Screening and prevention of ovarian cancer

Screening and prevention of ovarian cancer Chapter 2 Screening and prevention of ovarian cancer Prevention of ovarian carcinoma Oral contraceptive pills Use of oral contraceptive pills (OCPs) has been associated with a significant reduction in

More information

Utilization of BRCA Testing. Breast and Ovarian Cancer in Texas

Utilization of BRCA Testing. Breast and Ovarian Cancer in Texas Utilization of BRCA Testing in Older Ode Women with Breast and Ovarian Cancer in Texas Ana M. Rodriguez, MD Assistant Professor Department of Obstetrics and Gynecology University of Texas Medical Branch

More information

Salpingectomy for Sterilization

Salpingectomy for Sterilization Salpingectomy for Sterilization Change in Practice in a Large Integrated Health Care System 2011-2016 Journal Club November 15, 2017 Blaine Campbell, DO Salpingectomy for Sterilization: Change in Practice

More information

Cancer arising from Endometriosis and Its Clinical implications

Cancer arising from Endometriosis and Its Clinical implications Cancer arising from Endometriosis and Its Clinical implications 1) Nezhat F, Cohen C, Rahaman J, Gretz H, Cole P, Kalir T. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign

More information

--- or not, and do we need to come up with newer strategies for ovarian cancer screening.

--- or not, and do we need to come up with newer strategies for ovarian cancer screening. My name is Dr. Karen Lu and I am a Professor of Gynecologic Oncology at the University of Texas MD Anderson Cancer Center. I also serve as Co-Medical Director for Clinical Cancer Genetics. I m going to

More information

1. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45

1. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 1 2 3 1. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women

More information

Chapter 2: Initial treatment for endometrial cancer (including histologic variant type)

Chapter 2: Initial treatment for endometrial cancer (including histologic variant type) Chapter 2: Initial treatment for endometrial cancer (including histologic variant type) CQ01 Which surgical techniques for hysterectomy are recommended for patients considered to be stage I preoperatively?

More information

Partners: Introductions: Dr. Carolyn Johnston Deanna Cosens & Ann Garvin. Ovarian Cancer and Primary Care July 16, :00 9:00am EST 7/16/2014

Partners: Introductions: Dr. Carolyn Johnston Deanna Cosens & Ann Garvin. Ovarian Cancer and Primary Care July 16, :00 9:00am EST 7/16/2014 Welcome To The Webinar Technical Support Ovarian Cancer and Primary Care July 16, 2014 8:00 9:00am EST In order to hear the presentation please call 1 (626) 544-0058, access code 167-314-644, followed

More information

6 Week Course Agenda. Today s Agenda. Ovarian Cancer: Risk Factors. Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention

6 Week Course Agenda. Today s Agenda. Ovarian Cancer: Risk Factors. Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention 6 Week Course Agenda Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention Lee-may Chen, MD Director, Division of Gynecologic Oncology Professor Department of Obstetrics, Gynecology

More information

Unexpected Gynecologic Findings at Laparotomy. Susan A. Davidson, MD University of Colorado, Denver School of Medicine

Unexpected Gynecologic Findings at Laparotomy. Susan A. Davidson, MD University of Colorado, Denver School of Medicine Unexpected Gynecologic Findings at Laparotomy Susan A. Davidson, MD University of Colorado, Denver School of Medicine Adnexal Mass: Gyn Etiologies Uterine Leiomyomas Pregnancy Malignancy Tubal Pregnancy

More information

Hysterectomy Fact versus fiction. Richard Dover Specialist Gynaecologist

Hysterectomy Fact versus fiction. Richard Dover Specialist Gynaecologist Hysterectomy Fact versus fiction Richard Dover Specialist Gynaecologist Disclaimer Disclaimer Hysterectomy An update? Myths busted? HYSTERECTOMY Retro-chic! HMB Important cause of morbidity Affects

More information

Triage of Ovarian Masses. Andreas Obermair Brisbane

Triage of Ovarian Masses. Andreas Obermair Brisbane Triage of Ovarian Masses Andreas Obermair Brisbane Why Triage? In ovarian cancer, best outcomes for patients can be achieved when patients are treated in tertiary centres by a multidisciplinary team led

More information

Managing the adnexae at the time of hysterectomy for benign gynaecological disease

Managing the adnexae at the time of hysterectomy for benign gynaecological disease Managing the adnexae at the time of hysterectomy for benign gynaecological disease This statement has been developed and reviewed by the Women s Health Committee and approved by the RANZCOG Board and Council.

More information

Contents Introduction. Recommendations at a Glance. Introduction. Background. Clinical Recommendations

Contents Introduction. Recommendations at a Glance. Introduction. Background. Clinical Recommendations Salpingectomy for Ovarian Cancer Prevention May 2013 Contents Introduction Indications for Salpingectomy Technique Pathology Processing References, Authors, Appendix, Acknowledgements, and Disclaimer Recommendations

More information

of 20 to 80 and subsequently declines [2].

of 20 to 80 and subsequently declines [2]. - - According to the 2014 World Health Organization (WHO) classification and tumor morphology, primary ovarian tumors are subdivided into three categories: epithelial (60%), germ cell (30%), and sex-cord

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/24096

More information

Institute of Pathology First Faculty of Medicine Charles University. Ovary

Institute of Pathology First Faculty of Medicine Charles University. Ovary Ovary Barrett esophagus ph in vagina between 3.8 and 4.5 ph of stomach varies from 1-2 (hydrochloric acid) up to 4-5 BE probably results from upward migration of columnar cells from gastroesophageal junction

More information

Histopathological Study of Spectrum of Lesions Seen in Surgically Resected Specimens of Fallopian Tube

Histopathological Study of Spectrum of Lesions Seen in Surgically Resected Specimens of Fallopian Tube Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2016/613 Histopathological Study of Spectrum of Lesions Seen in Surgically Resected Specimens of Fallopian Tube Pratima

More information

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY Original Issue Date (Created): October 1, 2014 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT

More information

Christine Garcia, MD 1, Liisa Lyon, MS 2, Ramey D. Littell, MD 1 and C. Bethan Powell, MD 1

Christine Garcia, MD 1, Liisa Lyon, MS 2, Ramey D. Littell, MD 1 and C. Bethan Powell, MD 1 American College of Medical Genetics and Genomics Comparison of risk management strategies between women positive for a BRCA variant of unknown significance and women with known BRCA deleterious mutations

More information

Key Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer. HBOC related genes. I have nothing to disclose

Key Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer. HBOC related genes. I have nothing to disclose Gynecologic management of women with inherited risk of gynecologic cancer C. Bethan Powell MD Kaiser Permanente Northern California Gynecologic Oncology Program I have nothing to disclose Key Recommendations

More information

Case 1. Pathology of gynecological cancer. What do we need to know (Case 1) Luca Mazzucchelli Istituto cantonale di patologia Locarno

Case 1. Pathology of gynecological cancer. What do we need to know (Case 1) Luca Mazzucchelli Istituto cantonale di patologia Locarno Case 1 Pathology of gynecological cancer. What do we need to know (Case 1) Luca Mazzucchelli Istituto cantonale di patologia Locarno SAMO Interdisciplinary Workshop on Gynecological Tumors Lucern, October

More information

Public perception of risk-reducing salpingectomy for preventing ovarian cancer

Public perception of risk-reducing salpingectomy for preventing ovarian cancer Original Article Obstet Gynecol Sci 2015;58(4):284-288 http://dx.doi.org/10.5468/ogs.2015.58.4.284 pissn 2287-8572 eissn 2287-8580 Public perception of risk-reducing salpingectomy for preventing ovarian

More information

Ovarian Cancer Causes, Risk Factors, and Prevention

Ovarian Cancer Causes, Risk Factors, and Prevention Ovarian Cancer Causes, Risk Factors, and Prevention Risk Factors A risk factor is anything that affects your chance of getting a disease such as cancer. Learn more about the risk factors for ovarian cancer.

More information

Ovarian cancer: 2012 Update Srini Prasad MD Univ Texas MD Anderson Cancer Center

Ovarian cancer: 2012 Update Srini Prasad MD Univ Texas MD Anderson Cancer Center Ovarian cancer: 2012 Update Srini Prasad MD Univ Texas MD Anderson Cancer Center Ovarian cancer is not a single disease Ovarian Epithelial Tumors: Histological Spectrum* Type Frequency Histology High-Grade

More information

X-Plain Ovarian Cancer Reference Summary

X-Plain Ovarian Cancer Reference Summary X-Plain Ovarian Cancer Reference Summary Introduction Ovarian cancer is fairly rare. Ovarian cancer usually occurs in women who are over 50 years old and it may sometimes be hereditary. This reference

More information

QUT Digital Repository: This is the author version published as:

QUT Digital Repository:  This is the author version published as: QUT Digital Repository: http://eprints.qut.edu.au/ This is the author version published as: Bisseling, Karin and Kondalsamy-Chennakesavan, Srinivas and Bekkers, Ruud and Janda, Monika and Obermair, Andreas

More information

Clinical Study Laparoscopic Surgery in Elderly Patients Aged 65 Years and Older with Gynecologic Disease

Clinical Study Laparoscopic Surgery in Elderly Patients Aged 65 Years and Older with Gynecologic Disease International Scholarly Research Network ISRN Obstetrics and Gynecology Volume 2012, Article ID 678201, 4 pages doi:10.5402/2012/678201 Clinical Study Laparoscopic Surgery in Elderly Patients Aged 65 Years

More information

EDUCATIONAL COMMENTARY CA 125. Learning Outcomes

EDUCATIONAL COMMENTARY CA 125. Learning Outcomes EDUCATIONAL COMMENTARY CA 125 Learning Outcomes Upon completion of this exercise, participants will be able to: discuss the use of CA 125 levels in monitoring patients undergoing treatment for ovarian

More information

Interpretation of p53 Immunostains. P53 Mutations are Ubiquitous in High Grade Serous Carcinoma. Diffuse strong positive nuclear staining

Interpretation of p53 Immunostains. P53 Mutations are Ubiquitous in High Grade Serous Carcinoma. Diffuse strong positive nuclear staining Stains for Tumor Classification p53 p16 WT1 HMGA2 P53 Mutations are Ubiquitous in High Grade Serous Carcinoma Source Ahmed et al Australian Ovarian Cancer Study Cancer Genome Atlas Research Network Cases

More information

Primary Care Approach to Genetic Cancer Syndromes

Primary Care Approach to Genetic Cancer Syndromes Primary Care Approach to Genetic Cancer Syndromes Jason M. Goldman, MD, FACP FAU School of Medicine Syndromes Hereditary Breast and Ovarian Cancer (HBOC) Hereditary Nonpolyposis Colorectal Cancer (HNPCC)

More information

5/26/2016. Pelvic Serous Carcinoma: 2014 W.H.O. Update. Outline of Talk. Changes to 2014 WHO system for pelvic serous tumors

5/26/2016. Pelvic Serous Carcinoma: 2014 W.H.O. Update. Outline of Talk. Changes to 2014 WHO system for pelvic serous tumors Pelvic Serous Carcinoma: 2014 W.H.O. Update Outline of Talk Practical Implications for Pathologists Changes to 2014 WHO system for pelvic serous tumors High grade serous carcinoma versus low grade serous

More information

patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015

patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015 patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015 BRCA1 and BRCA2 Mutations Cancer is a complex disease thought to be caused by several different factors. A few types of cancer

More information

How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens

How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens Wenxin Zheng, M.D. Professor of Pathology and Gynecology University of Arizona zhengw@email.arizona.edu http://www.zheng.gynpath.medicine.arizona.edu/index.html

More information

RESEARCH COMMUNICATION

RESEARCH COMMUNICATION RESEARCH COMMUNICATION Clinicopathologic Analysis of Women with Synchronous Primary Carcinomas of the Endometrium and Ovary: 10- Year Experience from Chiang Mai University Hospital Jiraprapa Natee 1 *,

More information

Impact of Ovarian Endometrioma Per Se and Surgery on Ovarian Reserve and Pregnancy Rate in in Vitro Fertilization Cycles

Impact of Ovarian Endometrioma Per Se and Surgery on Ovarian Reserve and Pregnancy Rate in in Vitro Fertilization Cycles 1 st SEUD Meeting, 9 May 2015, Paris, France Impact of Ovarian Endometrioma Per Se and Surgery on Ovarian Reserve and Pregnancy Rate in in Vitro Fertilization Cycles ENDOMETRIOSIS ovarian endometrioma

More information

Policy #: 259 Latest Review Date: November 2009

Policy #: 259 Latest Review Date: November 2009 Name of Policy: Prophylactic Oophorectomy Policy #: 259 Latest Review Date: November 2009 Category: Surgery Policy Grade: Active Policy but no longer scheduled for regular literature reviews and updates.

More information

Female Genital Tract Lab. Dr. Nisreen Abu Shahin Assistant Professor of Pathology University of Jordan

Female Genital Tract Lab. Dr. Nisreen Abu Shahin Assistant Professor of Pathology University of Jordan Female Genital Tract Lab Dr. Nisreen Abu Shahin Assistant Professor of Pathology University of Jordan Ovarian Pathology A 20-year-old female presented with vague left pelvic pain. Pelvic exam revealed

More information

PRETREATMENT ASSESSMENT & MANAGEMENT (MODULE 1 B) March, 2018

PRETREATMENT ASSESSMENT & MANAGEMENT (MODULE 1 B) March, 2018 PRETREATMENT ASSESSMENT & MANAGEMENT (MODULE 1 B) March, 2018 Clinical Assessment A thorough clinical evaluation is a prerequisite for ART A thorough clinical evaluation as detailed in the female and male

More information

Clinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline ovarian tumors

Clinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline ovarian tumors REPRODUCTIVE SURGERY Clinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline ovarian tumors Yoav Yinon, M.D., Mario E. Beiner, M.D., Walter

More information

So, Who are the appropriate individuals that should consider genetic counseling and genetic testing?

So, Who are the appropriate individuals that should consider genetic counseling and genetic testing? Hello, I m Banu Arun, Professor of Breast Medical Oncology and Co-Director of Clinical Cancer Genetics at the University of Texas MD Anderson Cancer Center. Today I will be discussing with you Hereditary

More information

Hereditary Gynecologic Cancer 15 Years of Progress

Hereditary Gynecologic Cancer 15 Years of Progress Hereditary Gynecologic Cancer 15 Years of Progress Bethan Powell, M. D. Kaiser Permanente UCSF Gynecologic Cancer Risk Program Hereditary Gynecologic Cancer Syndromes BRCA 1 and 2: ovarian Lynch: ovarian/endometrial

More information

GENETIC MANAGEMENT OF A FAMILY HISTORY OF BREAST AND / OR OVARIAN CANCER. Dr Abhijit Dixit. Family Health Clinical Genetics

GENETIC MANAGEMENT OF A FAMILY HISTORY OF BREAST AND / OR OVARIAN CANCER. Dr Abhijit Dixit. Family Health Clinical Genetics GENETIC MANAGEMENT OF A FAMILY HISTORY OF BREAST AND / OR OVARIAN CANCER Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review

More information

Human epididymal protein 4 The role of HE4 in the management of patients presenting with pelvic mass Publication abstracts

Human epididymal protein 4 The role of HE4 in the management of patients presenting with pelvic mass Publication abstracts Human epididymal protein 4 The role of HE4 in the management of patients presenting with pelvic mass Publication abstracts Ovarian cancer is diagnosed annually in more than 200,000 women worldwide, with

More information

3 cell types in the normal ovary

3 cell types in the normal ovary Ovarian tumors 3 cell types in the normal ovary Surface (coelomic epithelium) the origin of the great majority of ovarian tumors (neoplasms) 90% of malignant ovarian tumors Totipotent germ cells Sex cord-stromal

More information

NATIONAL CLINICAL GUIDELINE INVESTIGATION AND MANAGEMENT OVARIAN CYSTS IN POSTMENOPAUSAL WOMEN

NATIONAL CLINICAL GUIDELINE INVESTIGATION AND MANAGEMENT OVARIAN CYSTS IN POSTMENOPAUSAL WOMEN NATIONAL CLINICAL GUIDELINE INVESTIGATION AND MANAGEMENT OF OVARIAN CYSTS IN POSTMENOPAUSAL WOMEN Institute of Obstetricians and Gynaecologists, Royal College of Physicians of Ireland and the Clinical

More information

Lavage of the uterine cavity as potential tool for diagnosis of epithelial ovarian cancer and its precursors

Lavage of the uterine cavity as potential tool for diagnosis of epithelial ovarian cancer and its precursors Lavage of the uterine cavity as potential tool for diagnosis of epithelial ovarian cancer and its precursors Gynecologic Cancer Intergroup GCIG 2013 Autumn Meeting London, UK November 17 th 2013 Type II

More information

Inherited Breast and Ovarian Cancer: 20 Years of Progress and Future Directions

Inherited Breast and Ovarian Cancer: 20 Years of Progress and Future Directions Inherited Breast and Ovarian Cancer: 20 Years of Progress and Future Directions Noah D. Kauff, MD, FACOG Director, Clinical Cancer Genetics Duke Cancer Institute / Duke University Health System Disclosures

More information

Histopathological Spectrum of Lesions in Fallopian Tube

Histopathological Spectrum of Lesions in Fallopian Tube IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 1 Ver. III (January. 2017), PP 75-80 www.iosrjournals.org Histopathological Spectrum of Lesions

More information

4:00 into mp3 file Huang_342831_5_v1.mp3

4:00 into mp3 file   Huang_342831_5_v1.mp3 Support for Yale Cancer Answers comes from AstraZeneca, providing important treatment options for women living with advanced ovarian cancer. Learn more at astrazeneca-us.com. Welcome to Yale Cancer Answers

More information

patient education Fact Sheet

patient education Fact Sheet patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations OCTOBER 2017 BRCA1 and BRCA2 Mutations Cancer is caused by several different factors. A few types of cancer run in families. These types are

More information

BRCA genes and inherited breast and ovarian cancer. Information for patients

BRCA genes and inherited breast and ovarian cancer. Information for patients BRCA genes and inherited breast and ovarian cancer Information for patients This booklet has been written for people who have a personal or family history of breast and/or ovarian cancer that could be

More information

Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact

Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact Bjørn Hagen, MD, PhD St Olavs Hospital Trondheim University Hospital Trondheim, Norway Endometrial Cancer (EC) The most

More information

Screening in Ovarian Cancer: Any closer to the Holy Grail?

Screening in Ovarian Cancer: Any closer to the Holy Grail? Screening in Ovarian Cancer: Any closer to the Holy Grail? Charles Chip Landen, Jr., M.D., M.S. Associate Professor, Departments of Obstetrics and Gynecology, and Pathology Associate Leader, Women s Oncology

More information

Potentials for iatrogenic ovarian hyporresponse following

Potentials for iatrogenic ovarian hyporresponse following Potentials for iatrogenic ovarian hyporresponse following endoscopic surgery Juan A Garcia-Velasco, MD IVI-Madrid, Rey Juan Carlos University Madrid, Spain Transition from 1980 s to 2007 Old aforism in

More information

GYNECOLOGIC MALIGNANCIES: Ovarian Cancer

GYNECOLOGIC MALIGNANCIES: Ovarian Cancer GYNECOLOGIC MALIGNANCIES: Ovarian Cancer KRISTEN STARBUCK, MD ROSWELL PARK CANCER INSTITUTE DEPARTMENT OF SURGERY DIVISION OF GYNECOLOGIC ONCOLOGY APRIL 19 TH, 2018 Objectives Basic Cancer Statistics Discuss

More information

Serous Tubal Intraepithelial Carcinoma in a Japanese Woman with a Deleterious BRCA1 Mutation

Serous Tubal Intraepithelial Carcinoma in a Japanese Woman with a Deleterious BRCA1 Mutation Japanese Journal of Clinical Oncology Advance Access published April 9, 2014 Jpn J Clin Oncol 2014 doi:10.1093/jjco/hyu035 Case Report Serous Tubal Intraepithelial Carcinoma in a Japanese Woman with a

More information

Evidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors.

Evidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors. Evidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors. Who needs surveillance? Chiarelli et al. Early menopause and Infertility

More information

Progress Update June 2017 Lay Summary Funding: $6,000,000 Grant Funded: July 2015 Dream Team Members Dream Team Leader:

Progress Update June 2017 Lay Summary Funding: $6,000,000 Grant Funded: July 2015 Dream Team Members Dream Team Leader: SU2C -Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant: DNA Repair Therapies for Ovarian Cancer AND SU2C Catalyst Merck-Supported Supplemental

More information

Female Sterilization. Kavita Nanda, MD, MHS FHI 360 Expanding Contraceptive Choice December 6, 2018

Female Sterilization. Kavita Nanda, MD, MHS FHI 360 Expanding Contraceptive Choice December 6, 2018 Female Sterilization Kavita Nanda, MD, MHS FHI 360 Expanding Contraceptive Choice December 6, 2018 What is female sterilization? Family planning method that provides permanent contraception to women and

More information

IMPLICACIONES DE LA OOFORECTOMÍA PROFILÁCTICA Y EL USO DE TRH SOBRE LA MORTALIDAD FEMENINA XIII

IMPLICACIONES DE LA OOFORECTOMÍA PROFILÁCTICA Y EL USO DE TRH SOBRE LA MORTALIDAD FEMENINA XIII IMPLICACIONES DE LA OOFORECTOMÍA PROFILÁCTICA Y EL USO DE TRH SOBRE LA MORTALIDAD FEMENINA XIII Congreso Costarricense de Climaterio Menopausia y osteoporosis 2014 Dr. Leonardo Orozco S. Colaboración Cochrane

More information

Section 1. Biology of gynaecological cancers: our current understanding

Section 1. Biology of gynaecological cancers: our current understanding Section 1 Biology of gynaecological cancers: our current understanding Chapter 1 Morphological sub-types of ovarian carcinoma: new developments and pathogenesis W Glenn McCluggage 1 Introduction In most

More information

Hereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families

Hereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families Hereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families What is Hereditary Breast and Ovarian Cancer (HBOC)? Hereditary Breast and Ovarian Cancer is a genetic condition which

More information

Tweetable abstract Opportunistic salpingectomy did not have any

Tweetable abstract Opportunistic salpingectomy did not have any DOI: 10.1111/1471-0528.14182 www.bjog.org Gynaesurgery Impact of opportunistic salpingectomy on anti-müllerian hormone in patients undergoing laparoscopic hysterectomy: a multicentre randomised controlled

More information

Characterizing Adnexal Masses: Pearls and Pitfalls 20 th Annual Summer Practicum SCBT-MR Jackson Hole August 11, 2010

Characterizing Adnexal Masses: Pearls and Pitfalls 20 th Annual Summer Practicum SCBT-MR Jackson Hole August 11, 2010 Characterizing Adnexal Masses: Pearls and Pitfalls 20 th Annual Summer Practicum SCBT-MR Jackson Hole August 11, 2010 Evan S. Siegelman MD University of Pennsylvania Medical Center Adnexal Masses: Pearls

More information

Managing infertility when adenomyosis and endometriosis co-exist

Managing infertility when adenomyosis and endometriosis co-exist Managing infertility when adenomyosis and endometriosis co-exist Jinhua Leng Beijing,China Endometriosis Endometriosis (EM) is a common, benign, ovary hormone-dependent gynecologic disorder which affects

More information

Melanoma-What Every Woman Need to Know about Fertility and Pregnancy

Melanoma-What Every Woman Need to Know about Fertility and Pregnancy Melanoma-What Every Woman Need to Know about Fertility and Pregnancy Women diagnosed with melanoma may require counseling for fertility preservation, fertility treatment and safety of pregnancy after treatment.

More information

Uterine Morcellation: Teasing Out the Issues

Uterine Morcellation: Teasing Out the Issues Uterine Morcellation: Teasing Out the Issues Stacey A. Scheib, MD, FACOG Director, Minimally Invasive Gynecology Director, Hopkins Multidisciplinary Fibroid Center Johns Hopkins Hospital Disclosures I

More information

CA125 in the diagnosis of ovarian cancer: the art in medicine

CA125 in the diagnosis of ovarian cancer: the art in medicine CA125 in the diagnosis of ovarian cancer: the art in medicine Dr Marcia Hall Consultant Medical Oncology Mount Vernon Cancer Centre Hillingdon Hospital Wexham Park Hospital Epidemiology Ovarian cancer

More information

PLACE AND MODALITIES OF LAPAROSCOPY IN SURGICAL MANAGEMENT OF SUSPECTED ADNEXAL MASSES

PLACE AND MODALITIES OF LAPAROSCOPY IN SURGICAL MANAGEMENT OF SUSPECTED ADNEXAL MASSES [Frontiers in Bioscience 1, g5-11, 1 December 1996] PLACE AND MODALITIES OF LAPAROSCOPY IN SURGICAL MANAGEMENT OF SUSPECTED ADNEXAL MASSES Charles Chapron 1, Jean-Bernard Dubuisson, Sylvie Capella-Allouc

More information

Gynecologic Quality Measures. David M. Jaspan, DO FACOOG Chairman The Department of Obstetrics and Gynecology The Einstein Healthcare Network

Gynecologic Quality Measures. David M. Jaspan, DO FACOOG Chairman The Department of Obstetrics and Gynecology The Einstein Healthcare Network Gynecologic Quality Measures David M. Jaspan, DO FACOOG Chairman The Department of Obstetrics and Gynecology The Einstein Healthcare Network Presenter Disclosure No Conflict of Interest to disclose No

More information

The Adnexal Mass. Handout NCUS 3/18/2017 Suzanne Dixon, MD

The Adnexal Mass. Handout NCUS 3/18/2017 Suzanne Dixon, MD The Adnexal Mass Handout NCUS 3/18/2017 Suzanne Dixon, MD Objectives: Pelvic mass differential Characteristics of the normal ovary Standard terminology for ovarian masses Benign vs. malignant features

More information

ACCME/Disclosures. Risk of Gyne Ca in HBOC. Molecular basis of HBOC. Hereditary Ovarian and Breast Cancer Syndrome

ACCME/Disclosures. Risk of Gyne Ca in HBOC. Molecular basis of HBOC. Hereditary Ovarian and Breast Cancer Syndrome Hereditary Ovarian and Breast Cancer Syndrome C. Blake Gilks, MD Dept of Pathology Vancouver General Hospital University of British Columbia Blake.gilks@vch.ca The USCAP requires that anyone in a position

More information